RxDoctor Payments Data

William Bloch, MD

Urology · Worthington, OHNPI 1023013505

Payments from drug & device makers

$8,165in general payments, 2019–2025

Across 353 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Procept Biorobotics Corporation$975
  • Sumitomo Pharma America, Inc.$716
  • Pfizer$525
  • Teleflex LLC$517
  • AbbVie$365
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$7429%
  • Food & beverage$6,97185%
  • Education$4516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,165 in reported general payments places this provider in the 70th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$414,923
Medicare patients
909
Services billed
11,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix42$115,575
GemtesaVibegron90$77,000
MyrbetriqMirabegron97$74,362
Tamsulosin Hcl747$9,749
Solifenacin Succinate104$5,055
Testosterone22$3,103
Bethanechol Chloride41$2,769
Oxybutynin Chloride ErOxybutynin Chloride129$2,371
Potassium Citrate ErPotassium Citrate29$2,332
Finasteride120$1,637
Estradiol24$1,458
Trimethoprim18$1,447
Alfuzosin Hcl ErAlfuzosin Hcl62$1,232
Oxybutynin Chloride107$1,179
Tadalafil18$1,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$716$192,575132 claims
Astellas Pharma US IncMyrbetriq$1,283$74,36297 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 485 urology providers in Ohio.

Other urology in Worthington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →